UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease

Acute Coronary Syndrome Main Page
Unstable angina / NSTEMI Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Unstable Angina
Non-ST Elevation Myocardial Infarction
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders
Epidemiology and Demographics
Risk Stratification
Natural History, Complications and Prognosis
Special Groups
Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Blood Studies
Biomarkers
Electrocardiogram
Chest X Ray
Echocardiography
Coronary Angiography
Treatment
Primary Prevention
Immediate Management
Anti-Ischemic and Analgesic Therapy
Cholesterol Management
Antitplatelet Therapy
Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor
Anticoagulant Therapy
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS
Mechanical Reperfusion
Initial Conservative Versus Initial Invasive Strategies
PCI
CABG
Complications of Bleeding and Transfusion
Discharge Care
Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation
Long-Term Medical Therapy and Secondary Prevention
ICD implantation within 40 days of myocardial infarction
ICD within 90 days of revascularization
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease
CDC onUA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease
UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease in the news
Blogs on UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease
to Hospitals Treating UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease
Risk calculators and risk factors for UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines chronic kidney disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

ACC / AHA Guidelines for Chronic Kidney Disease (DO NOT EDIT)

Class I

"1. Creatinine clearance should be estimated in UA/NSTEMI patients and the doses of renally cleared medications should be adjusted according to the pharmacokinetic data for specific medications. (Level B)"

"2. Patients undergoing cardiac catheterization with receipt of contrast media should receive adequate preparatory hydration. (Level B)"

"3. Calculation of the contrast volume to creatinine clearance ratio is useful to predict the maximum volume of contrast media that can be given without significantly increasing the risk of contrast-associated nephropathy. (Level B)"

Class IIa

"1. An invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD. (Level B) (There are insufficient data on benefit/risk of invasive strategy in UA/NSTEMI patients with advanced CKD [stages 4, 5].)"